Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
- PMID: 29685881
- DOI: 10.1158/1078-0432.CCR-18-0463
Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer
Abstract
Ribociclib is an orally active, highly selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6. It is the second CDK 4/6 inhibitor approved for hormone receptor-positive breast cancer. The addition of ribociclib to an aromatase inhibitor has resulted in marked improvements in progression-free survival for patients with metastatic breast cancer. Clin Cancer Res; 24(13); 2981-3. ©2018 AACRSee related article by Shah et al., p. 2999.
©2018 American Association for Cancer Research.
Comment on
-
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.Clin Cancer Res. 2018 Jul 1;24(13):2999-3004. doi: 10.1158/1078-0432.CCR-17-2369. Epub 2018 Feb 7. Clin Cancer Res. 2018. PMID: 29437768